Antimicrobial peptide LL-37 is produced in response to active vitamin D to exert immunomodulatory effects and inhibits HIV replication in vitro. To date, no studies have investigated LL-37 in HIV-infected patients. This study sought to investigate LL-37 and the relationship to 25-hydroxyvitamin D [25(OH)D] and HIV-related variables in this population. HIV-infected subjects and healthy controls ages 1–25 years old were prospectively enrolled in this cross-sectional study. Fasting plasma LL-37 and 25(OH)D concentrations were measured in duplicate with ELISA. HIV+ subjects (36 antiretroviral therapy (ART)-experienced subjects; 27 ART-naïve subjects) and 31 healthy controls were enrolled. Overall, 93% were black and the median age was 20 years. There was no difference in median (interquartile range) LL-37 between the HIV-infected group and controls [58.3 (46.4,69.5) vs. 51.3 (40.8,98.2) ng/ml, respectively; p=0.57]; however, the ART-experienced group had higher concentrations than the ART-naive group [66.2 (55.4,77.0) vs. 48.9 (38.9,57.9) ng/ml, respectively; p<0.001]. LL-37 was positively correlated with 25(OH)D in controls, but not in HIV-infected groups, and was positively correlated with current CD4 and ΔCD4 (current-nadir) in the ART-experienced group. After adjustment for age, race, sex, and HIV duration, the association between LL-37 and CD4 remained significant. These findings suggest that HIV and/or HIV-related variables may alter the expected positive relationship between vitamin D and LL-37 and should be further investigated.
Get full access to this article
View all access options for this article.
References
1.
StephensenCB, MarquisGS, KruzichLA, DouglasSD, AldrovandiGM, and WilsonCM: Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr, 2006; 83(5):1135–1141.
2.
RossAC, JuddS, KumariM, et al.: Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther, 2011; 16(4):555–563.
3.
RutsteinR, DownesA, ZemelB, SchallJ, and StallingsV: Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr, 2011; 30(5):624–628.
4.
EckardAR, JuddSE, ZieglerTR, et al.: Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther, 2012; 17(6):1069–1078.
5.
BrownTT and McComseyGA: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther, 2010; 15(3):425–429.
6.
HolickMF: Vitamin D deficiency. N Engl J Med, 2007; 357(3):266–281.
7.
SchleithoffSS, ZittermannA, TenderichG, BertholdHK, StehleP, and KoerferR: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr, 2006; 83(4):754–759.
8.
KamenDL and TangprichaV: Vitamin D and molecular actions on the immune system: Modulation of innate and autoimmunity. J Mol Med (Berl), 2010; 88(5):441–450.
9.
van EttenE, StoffelsK, GysemansC, MathieuC, and OverberghL: Regulation of vitamin D homeostasis: Implications for the immune system. Nutr Rev, 2008; 66(10Suppl 2):S125–134.
10.
KhazaiN, JuddSE, and TangprichaV: Calcium and vitamin D: Skeletal and extraskeletal health. Curr Rheumatol Rep, 2008; 10(2):110–117.
11.
WilkinsonRJ, LlewelynM, ToossiZ, et al.: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. Lancet, 2000; 355(9204):618–621.
12.
DaviesPD, BrownRC, and WoodheadJS: Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax, 1985; 40(3):187–190.
13.
CannellJJ, HollisBW, ZasloffM, and HeaneyRP: Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother, 2008; 9(1):107–118.
WilliamsB, WilliamsAJ, and AndersonST: Vitamin D deficiency and insufficiency in children with tuberculosis. Pediatr Infect Dis J, 2008; 27(10):941–942.
16.
MuheL, LulsegedS, MasonKE, and SimoesEA: Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet, 1997; 349(9068):1801–1804.
17.
MehtaS, GiovannucciE, MugusiFM, et al.: Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One, 2010; 5(1):e8770.
18.
ViardJP, SouberbielleJC, KirkO, et al.: Vitamin D and clinical disease progression in HIV infection: Results from the EuroSIDA study. AIDS, 2011; 25(10):1305–1315.
19.
CampbellGR and SpectorSA: Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem, 2011; 286(21):18890–18902.
20.
LiuPT, StengerS, TangDH, and ModlinRL: Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol, 2007; 179(4):2060–2063.
21.
YukJM, ShinDM, LeeHM, et al.: Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe, 2009; 6(3):231–243.
22.
BergmanP, Walter-JallowL, BrolidenK, AgerberthB, and SoderlundJ: The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res, 2007; 5(4):410–415.
23.
GrossmannRE, ZughaierSM, LiuS, LylesRH, and TangprichaV: Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr, 2012; 66(9):1072–1074.
24.
JengL, YamshchikovAV, JuddSE, et al.: Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med, 2009; 7:28.
25.
YamshchikovAV, KurbatovaEV, KumariM, et al.: Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr, 2010; 92(3):603–611.
26.
RossAC, RizkN, O'RiordanMA, et al.: Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis, 2009; 49(7):1119–1127.
27.
RossAC, ArmentroutR, O'RiordanMA, et al.: Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr, 2008; 49(5):499–506.
28.
Institute of Medicine (U.S.): Dietary Reference Intakes for Calcium and Vitamin D.The National Academies Press, Washington, D.C., 2011.
29.
de LuisDA, BachillerP, AllerR, et al.: [Relation among micronutrient intakes with CD4 count in HIV infected patients]. Nutr Hosp, 2002; 17(6):285–289.
30.
SteinEM, YinMT, McMahonDJ, et al.: Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int, 2011; 22(2):477–487.
31.
TeichmannJ, StephanE, DischerT, et al.: Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism, 2000; 49(9):1134–1139.
32.
van den Bout-van den BeukelCJ, van den BosM, OyenWJ, et al.: The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med, 2008; 9(9):771–779.
33.
ArpadiSM, McMahonD, AbramsEJ, et al.: Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics, 2009; 123(1):e121–126.
34.
KakaliaS, SochettEB, StephensD, AssorE, ReadSE, and BitnunA: Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr, 2011; 159(6):951–957.
35.
PoweCE, EvansMK, WengerJ, et al.: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med, 2013; 369(21):1991–2000.
36.
Serrano-VillarS, GutierrezC, VallejoA, et al.: The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect, 2013; 66(1):57–66.
37.
RayA, TatterSB, SanthanamU, HelfgottDC, MayLT, and SehgalPB: Regulation of expression of interleukin-6. Molecular and clinical studies. Ann NY Acad Sci, 1989; 557:353–361; discussion 361–362.
38.
Frohm NilssonM, SandstedtB, SorensenO, WeberG, BorregaardN, and Stahle-BackdahlM: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun, 1999; 67(5):2561–2566.
39.
KruegerJ, RayA, TammI, and SehgalPB: Expression and function of interleukin-6 in epithelial cells. J Cell Biochem, 1991; 45(4):327–334.
40.
InomataM, IntoT, and MurakamiY: Suppressive effect of the antimicrobial peptide LL-37 on expression of IL-6, IL-8 and CXCL10 induced by Porphyromonas gingivalis cells and extracts in human gingival fibroblasts. Eur J Oral Sci, 2010; 118(6):574–581.
41.
PistolicJ, CosseauC, LiY, et al.: Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF-kappaB signaling pathway. J Innate Immun, 2009; 1(3):254–267.
